Gfrα1 Is Required for Development of Distinct Subpopulations of Motoneuron

Total Page:16

File Type:pdf, Size:1020Kb

Gfrα1 Is Required for Development of Distinct Subpopulations of Motoneuron The Journal of Neuroscience, July 1, 2000, 20(13):4992–5000 GFR␣1 Is Required for Development of Distinct Subpopulations of Motoneuron A. Garce`s,1 G. Haase,1 M. S. Airaksinen,2 J. Livet,1 P. Filippi,1 and O. deLapeyrie`re1 1Institut National de la Sante´ et de la Recherche Me´ dicale (INSERM) U.382, Developmental Biology Institute of Marseille (Centre National de la Recherche Scientifique-INSERM-Universite´ delaMe´ diterrane´ e, AP de Marseille), Campus de Luminy, 13288 Marseille Cedex 09, France, and 2Institute of Biotechnology, Viikki Biocenter, University of Helsinki, Helsinki FIN-00014, Finland Glial cell-line derived neurotrophic factor (GDNF) and its relative is absolutely required for the survival response of a majority of neurturin (NTN) are potent trophic factors for motoneurons. motoneurons to both GDNF and NTN. In accordance with the They exert their biological effects by activating the RET tyrosine phenotype of the mutant motoneurons observed in culture we kinase in the presence of a glycosyl-phosphatidylinositol-linked found the loss of distinct groups of motoneurons, identified by co-receptor, either GFR␣1orGFR␣2. By whole-mount in situ several markers, in the Gfra1 Ϫ /Ϫ spinal cords but no gross hybridization on embryonic mouse spinal cord, we demonstrate defects in the Gfra2 Ϫ /Ϫ mutant. During their natural pro- that whereas Ret is expressed by nearly all motoneurons, Gfra1 grammed cell death period, motoneurons in the Gfra1 Ϫ /Ϫ mu- and Gfra2 exhibit complex and distinct patterns of expression. tant mice undertook increased apoptosis. Taken together these Most motoneurons purified from Gfra1 null mutant mice had findings support the existence of subpopulations of motoneu- lost their responsiveness to both GDNF and NTN. However, a ron with different trophic requirements, some of them being minority of them (ϳ25%) retained their ability to respond to dependent on the GDNF family. both factors, perhaps because they express GFR␣2. Surpris- Key words: motoneuron subpopulations; motoneuron sur- ingly, Gfra2 Ϫ /Ϫ motoneurons showed normal survival re- vival; neurotrophic factors; GDNF; NTN; Ret; Gfra1; Gfra2; in sponses to both GDNF and NTN. Thus, GFR␣1, but not GFR␣2, situ hybridization; mutant mice Spinal motoneurons are organized into discrete longitudinal col- original member of a family distantly related to transforming umns that contain pools of motoneurons distributed along the growth factor-␤, which at present includes three additional mem- dorsoventral, rostrocaudal and mediolateral body axes according bers: NTN, persephin (PSP), and artemin (ART) (Lin et al., to their target muscles. In the embryo, motor columns can be 1993; Kotzbauer et al., 1996; Baloh et al., 1998; Milbrandt et al., distinguished by the combinatorial expression of members of a 1998). Members of this family are potent survival factors for family of LIM homeodomain proteins, called the LIM code several populations of central and peripheral neurons. In partic- (Tsuchida et al., 1994). Recently, transcription factors belonging ular, GDNF, NTN, and PSP have potent effects on the survival of to the Ets family have been shown to be expressed by individual motoneurons either in vivo or in vitro (Henderson et al., 1994; motor pools (Lin et al., 1998). Oppenheim et al., 1995; Yan et al., 1995; Klein et al., 1997; Because different subpopulations of motoneuron can also be Milbrandt et al., 1998). distinguished by the receptors for neurotrophic factors they syn- The actions of GDNF and its relatives are mediated by a thesize (Yamamoto et al., 1997), we hypothesized that these receptor complex consisting of the tyrosine kinase receptor RET different subpopulations of motoneuron might have different tro- and a ligand-binding glycosyl-phosphatidylinositol (GPI)-linked phic requirements. To test this hypothesis we focused on two protein (GFR␣). There are multiple GFR␣ proteins: GFR␣1, 2, members of the glial cell line-derived neurotrophic factor 3 and 4. In vitro experiments indicate that GFR␣1 and 2 are the (GDNF) family: GDNF and neurturin (NTN). GDNF is the favored receptors for GDNF and NTN, respectively. Compari- son of the phenotypes of mutant mice lacking either the ligand or ␣ Received Jan. 10, 2000; revised March 30, 2000; accepted April 5, 2000. the GFR receptor highlighted the preferential interaction be- This work was supported by Institut National de la Sante´ et de la Recherche tween GDNF and GFR␣1 and NTN and GFR␣2 (for review, see Me´dicale (INSERM), Centre National de la Recherche Scientifique (CNRS), the Airaksinen et al., 1999). However, at high concentrations GDNF Association Franc¸aise contre les Myopathies (AFM), the Institut pour la Recherche ␣ sur la Moelle Epinie`re (IRME), Academy of Finland, and European Community can signal after binding to GFR 2 (Baloh et al., 1997; Jing et al., contract CT960433. A.G. and J.L. were supported by French Ministe`redela 1997; Sanicola et al., 1997), and NTN can bind to GFR␣1 Recherche et de la Technologie, and G.H. by AFM and the Fondation pour la (Creedon et al., 1997; Jing et al., 1997). In accordance with the Recherche Me´dicale. A.G. was further supported by Association de Recherche contre le Cancer. We thank Chris Henderson and members of INSERM U.382 for biological activities of GDNF and NTN, Gfra1 and 2 are widely many helpful discussions and encouraging support. We acknowledge generous gifts ϩ Ϫ distributed in both the PNS and CNS (Treanor et al., 1996; Baloh of Gfra1 / mice from A. Rosenthal (Genentech, San Francisco, CA) and A. Davies (University of St. Andrews). et al., 1997; Klein et al., 1997; Trupp et al., 1997; Widenfalk et al., Correspondence should be addressed to O. deLapeyrie`re, Institut National de la 1997; Yu et al., 1998; Soler et al., 1999). Sante´ et de la Recherche Me´dicale U.382, Institut de Biologie du De´veloppement de In the chick, Gfra receptors are expressed in different subpopu- Marseille, Campus de Luminy, Case 907, 13288 Marseille Cedex 09, France. E-mail: [email protected]. lations of motoneuron (Soler et al., 1999) in accordance with the Copyright © 2000 Society for Neuroscience 0270-6474/00/204992-09$15.00/0 complementary and sometimes overlapping patterns of expres- Garce` s et al. • Subsets of Motoneuron Lost in Gfra1Ϫ/Ϫ Mice J. Neurosci., July 1, 2000, 20(13):4992–5000 4993 sion of Gfra1 and Gfra2 we have observed in the rat embryonic MO), and human BDNF was purchased fromR&DSystems (Minne- spinal cord (our unpublished observations). In particular, in the apolis, MN). Human NTN was either generously provided by Genentech rat lumbar region there are subpopulations of motoneuron that or purchased from Peprotech (London, UK). Neurotrophic factors were prepared as stock solutions (1–100 ␮g/ml) in PBS supplemented with express mRNA coding for one receptor but not for the other. 0.5% BSA (Sigma) and kept in aliquots at Ϫ70°C. Once thawed, aliquots These results raised the possibility that there might be two classes were kept at 4°C and used within 1 week. of lumbar motoneurons: one sustained by GDNF acting through Probes. Plasmid cDNA clones were linearized and transcribed with T7 GFR␣1 and the other by NTN acting through GFR␣2. The best or T3 polymerase using digoxigenin (DIG)-labeling reagents (Roche way of testing this hypothesis is by genetic analysis in the mouse. Diagnostics, Meylan, France). Probes were used at a concentration between 10 and 500 ng/ml. The Gfra1 and Ret clones were as previously We therefore chose to study the patterns of GDNF family recep- described (Arce et al., 1998). The rat Gfra2 probe corresponded to nt tor expression in mouse spinal cord and to analyze the effects of 1–1297 (GenBank accession number AF005226). The rat Islet1 probe null mutations in Gfra1 and Gfra2 on survival of specific mo- (Pfaff et al., 1996) and a 600 bp fragment of the mouse Raldh2 cDNA toneuron subpopulations. were kindly provided by T. M. Jessell. The mouse EphA4 corresponded It has been indeed reported that Gdnf and Gfra1 knock-out to nt 652–1834 and was generously given by P. Charnay. In situ hybridization. Whole-mount in situ hybridization (ISH) was mice show a loss of 25% of motoneurons in lumbar spinal cord, performed as described by Henrique et al. (1995). Spinal cords were but the missing population has not been identified (Moore et al., dissected, and fixed overnight at 4°C in 4% (w/v) paraformaldehyde in 1996; Sanchez et al., 1996; Cacalano et al., 1998). We show that PBT (0.1% Tween 20 in PBS), progressively dehydrated in increasing GFR␣1 is required for survival signaling by both GDNF and concentrations of ethanol/PBT, stored at Ϫ20°C, then rehydrated in NTN in spinal motoneurons. Furthermore, prominent motoneu- decreasing concentrations of ethanol/PBT and treated with proteinase K (10 ␮g/ml in PBS). They were then post-fixed for 20 min in 4% parafor- ron groups that strongly express Gfra1 (but not Gfra2) are lost in maldehyde, 0.1% glutaraldehyde, and 0.1% Tween 20 and prehybridized Ϫ /Ϫ the Gfra1 mutant, whereas other motoneurons are apparently 1 hr at 70°C in 1.3ϫ SSC, 50% formamide, 2% Tween 20, 0.5% 3-[(3- unaffected. Thus, GFR␣1 is critical for the survival of specific cholamidopropyl)dimethylammonio]-1-propanesulfonic acid, 5 mM groups of motoneuron during development, and different mo- EDTA, and 50 ␮g/ml yeast RNA. Hybridization was performed over- toneurons have clearly different trophic requirements in vivo. night with DIG-labeled riboprobes in the same buffer. Washes with hybridization buffer were followed by RNase A treatment (10 ␮g/ml in 0.5 M NaCl, 10 mM Tris, pH 7.5, and 0.1% Tween 20, 1 hr at 37°C), and MATERIALS AND METHODS subsequent washes with hybridization buffer at 65°C.
Recommended publications
  • Supp Material.Pdf
    Legends for Supplemental Figures and Tables Figure S1. Expression of Tlx during retinogenesis. (A) Staged embryos were stained for β- galactosidase knocked into the Tlx locus to indicate Tlx expression. Tlx was expressed in the neural blast layer in the early phase of neural retina development (blue signal). (B) Expression of Tlx in neural retina was quantified using Q-PCR at multiple developmental stages. Figure S2. Expression of p27kip1 and cyclin D1 (Ccnd1) at various developmental stages in wild-type or Tlx-/- retinas. (A) Q-PCR analysis of p27kip1 mRNA expression. (B) Western blotting analysis of p27kip1 protein expression. (C) Q-PCR analysis of cyclin D1 mRNA expression. Figure S3. Q-PCR analysis of mRNA expression of Sf1 (A), Lrh1 (B), and Atn1 (C) in wild-type mouse retinas. RNAs from testis and liver were used as controls. Table S1. List of genes dysregulated both at E15.5 and P0 Tlx-/- retinas. Gene E15.5 P0 Cluste Gene Title Fold Fold r Name p-value p-value Change Change nuclear receptor subfamily 0, group B, Nr0b1 1.65 0.0024 2.99 0.0035 member 1 1 Pou4f3 1.91 0.0162 2.39 0.0031 POU domain, class 4, transcription factor 3 1 Tcfap2d 2.18 0.0000 2.37 0.0001 transcription factor AP-2, delta 1 Zic5 1.66 0.0002 2.02 0.0218 zinc finger protein of the cerebellum 5 1 Zfpm1 1.85 0.0030 1.88 0.0025 zinc finger protein, multitype 1 1 Pten 1.60 0.0155 1.82 0.0131 phospatase and tensin homolog 2 Itgb5 -1.85 0.0063 -1.85 0.0007 integrin beta 5 2 Gpr49 6.86 0.0001 15.16 0.0001 G protein-coupled receptor 49 3 Cmkor1 2.60 0.0007 2.72 0.0013
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Gene Expression Profiles of Estrogen Receptor–Positive and Estrogen Receptor–Negative Breast Cancers Are Detectable in Histologically Normal Breast Epithelium
    Published OnlineFirst November 8, 2010; DOI: 10.1158/1078-0432.CCR-10-1369 Clinical Cancer Human Cancer Biology Research Gene Expression Profiles of Estrogen Receptor–Positive and Estrogen Receptor–Negative Breast Cancers Are Detectable in Histologically Normal Breast Epithelium Kelly Graham1, Xijin Ge4, Antonio de las Morenas2, Anusri Tripathi3, and Carol L. Rosenberg1,2,3 Abstract Purpose: Previously, we found that gene expression in histologically normal breast epithelium (NlEpi) from women at high breast cancer risk can resemble gene expression in NlEpi from cancer-containing breasts. Therefore, we hypothesized that gene expression characteristic of a cancer subtype might be seen in NlEpi of breasts containing that subtype. Experimental Design: We examined gene expression in 46 cases of microdissected NlEpi from untreated women undergoing breast cancer surgery. From 30 age-matched cases [15 estrogen receptor (ER)þ,15ERÀ] we used Affymetryix U133A arrays. From 16 independent cases (9 ERþ,7ERÀ), we validated selected genes using quantitative real-time PCR (qPCR). We then compared gene expression between NlEpi and invasive breast cancer using four publicly available data sets. Results: We identified 198 genes that are differentially expressed between NlEpi from breasts with ERþ (NlEpiERþ) compared with ERÀ cancers (NlEpiERÀ). These include genes characteristic of ERþ and ERÀ cancers (e.g., ESR1, GATA3, and CX3CL1, FABP7). qPCR validated the microarray results in both the 30 original cases and the 16 independent cases. Gene expression in NlEpiERþ and NlEpiERÀ resembled gene expression in ERþ and ERÀ cancers, respectively: 25% to 53% of the genes or probes examined in four external data sets overlapped between NlEpi and the corresponding cancer subtype.
    [Show full text]
  • Supplementary Table 1. Pain and PTSS Associated Genes (N = 604
    Supplementary Table 1. Pain and PTSS associated genes (n = 604) compiled from three established pain gene databases (PainNetworks,[61] Algynomics,[52] and PainGenes[42]) and one PTSS gene database (PTSDgene[88]). These genes were used in in silico analyses aimed at identifying miRNA that are predicted to preferentially target this list genes vs. a random set of genes (of the same length). ABCC4 ACE2 ACHE ACPP ACSL1 ADAM11 ADAMTS5 ADCY5 ADCYAP1 ADCYAP1R1 ADM ADORA2A ADORA2B ADRA1A ADRA1B ADRA1D ADRA2A ADRA2C ADRB1 ADRB2 ADRB3 ADRBK1 ADRBK2 AGTR2 ALOX12 ANO1 ANO3 APOE APP AQP1 AQP4 ARL5B ARRB1 ARRB2 ASIC1 ASIC2 ATF1 ATF3 ATF6B ATP1A1 ATP1B3 ATP2B1 ATP6V1A ATP6V1B2 ATP6V1G2 AVPR1A AVPR2 BACE1 BAMBI BDKRB2 BDNF BHLHE22 BTG2 CA8 CACNA1A CACNA1B CACNA1C CACNA1E CACNA1G CACNA1H CACNA2D1 CACNA2D2 CACNA2D3 CACNB3 CACNG2 CALB1 CALCRL CALM2 CAMK2A CAMK2B CAMK4 CAT CCK CCKAR CCKBR CCL2 CCL3 CCL4 CCR1 CCR7 CD274 CD38 CD4 CD40 CDH11 CDK5 CDK5R1 CDKN1A CHRM1 CHRM2 CHRM3 CHRM5 CHRNA5 CHRNA7 CHRNB2 CHRNB4 CHUK CLCN6 CLOCK CNGA3 CNR1 COL11A2 COL9A1 COMT COQ10A CPN1 CPS1 CREB1 CRH CRHBP CRHR1 CRHR2 CRIP2 CRYAA CSF2 CSF2RB CSK CSMD1 CSNK1A1 CSNK1E CTSB CTSS CX3CL1 CXCL5 CXCR3 CXCR4 CYBB CYP19A1 CYP2D6 CYP3A4 DAB1 DAO DBH DBI DICER1 DISC1 DLG2 DLG4 DPCR1 DPP4 DRD1 DRD2 DRD3 DRD4 DRGX DTNBP1 DUSP6 ECE2 EDN1 EDNRA EDNRB EFNB1 EFNB2 EGF EGFR EGR1 EGR3 ENPP2 EPB41L2 EPHB1 EPHB2 EPHB3 EPHB4 EPHB6 EPHX2 ERBB2 ERBB4 EREG ESR1 ESR2 ETV1 EZR F2R F2RL1 F2RL2 FAAH FAM19A4 FGF2 FKBP5 FLOT1 FMR1 FOS FOSB FOSL2 FOXN1 FRMPD4 FSTL1 FYN GABARAPL1 GABBR1 GABBR2 GABRA2 GABRA4
    [Show full text]
  • (GFRA2) (NM 001495) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC208014L4 GDNF Receptor alpha 2 (GFRA2) (NM_001495) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: GDNF Receptor alpha 2 (GFRA2) (NM_001495) Human Tagged ORF Clone Tag: mGFP Symbol: GFRA2 Synonyms: GDNFRB; NRTNR-ALPHA; NTNRA; RETL2; TRNR2 Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC208014). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_001495 ORF Size: 1392 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 GDNF Receptor alpha 2 (GFRA2) (NM_001495) Human Tagged ORF Clone – RC208014L4 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_001495.4 RefSeq Size: 3376 bp RefSeq ORF: 1395 bp Locus ID: 2675 UniProt ID: O00451 Domains: GDNF Protein Families: Druggable Genome MW: 51.5 kDa Gene Summary: Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) are two structurally related, potent neurotrophic factors that play key roles in the control of neuron survival and differentiation.
    [Show full text]
  • Table SI. Characteristics of 9 Patients Chosen from 60 Patients with Hepatocellular Carcinoma
    Table SI. Characteristics of 9 patients chosen from 60 patients with hepatocellular carcinoma. Characteristic No. of patients (%) Age, years <50 3 (33.3) ≥50 6 (66.7) Sex Female 4 (44.4) Male 5 (55.6) Albumin, g/l ≥35 8 (88.9) <35 1 (11.1) AFP, ng/ml ≤20 2 (22.2) >20 7 (77.8) Tumor diameter, cm ≤5 3 (33.3) >5 6 (66.7) Portal vein invasion Without 3 (33.3) With 6 (66.7) BCLC stage A 2 (22.2) B/C 7 (77.8) AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer. Table SII. List of the gene symbol and relative expression of six significant clusters. Gene symbol SPOT Profile Day 0 Day 3 Day 7 Day 14 Day 21 ALCAM ID_10 16 0 -356.5 378.5 0.1 307.8 ANGPT2 ID_13 16 0 -45.7 197.2 96 60.2 CD80 ID_24 16 0 -177 362 -29 187 CTNNB1 ID_29 16 0 -58 294 83 49 BMP4 ID_37 16 0 -107 189 0 53 CCL28 ID_49 16 0 -307 856 491 347 CCR1 ID_50 16 0 -189 391 236 112 CCR4 ID_53 16 0 -101 361 89 240 CCR7 ID_56 16 0 -98 361 103 66 CLC ID_70 16 0 -147 274 0 188 CRIM1 ID_74 16 0 -642 229 -48 -112 CXCL14 ID_83 16 0 -434 1,154.00 778 376 CXCL16 ID_84 16 0 -128 800 477 180 DKK3 ID_97 16 0 -199 610 107 3 FGFBP1 ID_129 16 0 -224 484 -155 37 FGF20 ID_147 16 0 -113 264 -32 -4 WFIKKN1 ID_163 16 0 -195 544 262 41 GFRA1 ID_175 16 0 -536 443 29 280 GFRA4 ID_178 16 0 -211 208 -47 116 TNFSF18 ID_180 16 0 -14 246 89 68 GPC5 ID_187 16 0 -180 1,345.00 298 509 GH1 ID_194 16 0 -596 206 10 -9 CCHCR1 ID_198 16 0 -108 322 50 238 NRG1 ID_200 16 0 -81 378.5 170.5 187 ICAM1 ID_207 16 0 -136 98 -17 63 IFNB1 ID_213 16 0 -87 233 143 29 IGFBP3 ID_218 16 0 -1,311.00 609 -368 -178 IGFBP4 ID_219 16 0
    [Show full text]
  • Gene Expression Profiling Reveals Early Induction of Genes Involved in Lipid Transport and Metabolism
    Erythropoietin increases myelination in oligodendrocytes: gene expression profiling reveals early induction of genes involved in lipid transport and metabolism Article (Published Version) Gyetvai, Georgina, Hughe, Tricia, Wedmore, Florence, Roe, Cieron, Heikal, Lamia, Ghezzi, Pietro and Mengozzi, Manuela (2017) Erythropoietin increases myelination in oligodendrocytes: gene expression profiling reveals early induction of genes involved in lipid transport and metabolism. Frontiers in Immunology, 8 (1394). pp. 1-13. ISSN 1664-3224 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/70476/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
    [Show full text]
  • Logistic Regression Analysis for the Identification of the Metastasis-Associated Signaling Pathways of Osteosarcoma
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 41: 1233-1244, 2018 Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma YANG LIU1, WEI SUN2, XIAOJUN MA2, YUEDONG HAO3, GANG LIU3, XIAOHUI HU3, HOULAI SHANG3, PENGFEI WU3, ZEXUE ZHAO3 and WEIDONG LIU3 1Department of Orthopedics, Affiliated Hospital of Inner Mongolia University for The Nationalities, Tongliao, Inner Mongolia 028007; 2Department of Orthopaedics, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080; 3Department of Orthopedics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China Received February 20, 2017; Accepted September 26, 2017 DOI: 10.3892/ijmm.2018.3360 Abstract. Osteosarcoma (OS) is the most common histological migration were identified as the terms that were significantly type of primary bone cancer. The present study was designed different. ICAM1, PDGFB, PDGFRB and TGFB1 were iden- to identify the key genes and signaling pathways involved in the tified to be enriched in cell migration and regulation of cell metastasis of OS. Microarray data of GSE39055 were down- migration. Nucleotide excision repair and the Wnt signaling loaded from the Gene Expression Omnibus database, which pathway were the metastasis-associated pathways of OS. In included 19 OS biopsy specimens before metastasis (control addition, ICAM1, PDGFB, PDGFRB and TGFB1, which were group) and 18 OS biopsy specimens after metastasis (case involved in cell migration and regulation of cell migration may group). After the differentially expressed genes (DEGs) were affect the metastasis of OS. identified using the Linear Models for Microarray Analysis package, hierarchical clustering analysis and unsupervised Introduction clustering analysis were performed separately, using orange software and the self-organization map method.
    [Show full text]
  • Supplementary Table 1: Genes Affected by Anoikis. A, Ratio of Signal
    Supplementary Table 1: Genes affected by anoikis. a, ratio of signal intensity of nonanchored cells anchorage dependent cells (CasKoSrc) over anchored cells; b, induced by Src transformation of Cx43KO cells; c, decreased by Src transformation of Cx43Ko cells; *, induced by normalization of Src transformed cells by neighboring nontransformed cells. Gene Symbol Probe Set Fold Changea Gene Name increased Selenbp1 1450699_at 23.22 selenium binding protein 1 Dscr1l1 1450243_a_at 10.77 Down syndrome critical region gene 1-like 1 Dscr1l1 1421425_a_at 4.29 Down syndrome critical region gene 1-like 1 Ttyh1 1426617_a_at 6.70 tweety homolog 1 (Drosophila) 5730521E12Rik 1419065_at 6.16 RIKEN cDNA 5730521E12 gene c 6330406I15Rik 1452244_at 5.87 RIKEN cDNA 6330406I15 gene AF067063 1425160_at 5.73 clone L2 uniform group of 2-cell-stage gene family mRNA Morc 1419418_a_at 5.55 microrchidia c Gpr56 1421118_a_at 5.43 G protein-coupled receptor 56 Pax6 1452526_a_at 5.06 paired box gene 6 Tgfbi 1415871_at 3.73 transforming growth factor beta induced Adarb1 1434932_at 3.70 adenosine deaminase RNA-specific B1 Ddx3y 1452077_at 3.30 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 Y-linked b Ampd3 1422573_at 3.20 AMP deaminase 3 Gli2 1459211_at 3.07 GLI-Kruppel family member GLI2 Selenbp2 1417580_s_at 2.96 selenium binding protein 2 Adamts1 1450716_at 2.80 a disintegrin-like and metalloprotease with thrombospondin type 1 motif 1 Dusp15 1426189_at 2.70 dual specificity phosphatase-like 15 Dpep3 1429035_at 2.60 dipeptidase 3 Sepp1 1452141_a_at 2.57 selenoprotein P plasma
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Ssecks/Gravin/AKAP12 Attenuates Expression of Proliferative And
    BMC Cancer BioMed Central Research article Open Access SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis Yongzhong Liu1, Lingqiu Gao2 and Irwin H Gelman*2 Address: 1Mucosal Immunology Unit, National Institutes of Health, Bethesda, MD 20892, USA and 2Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA Email: Yongzhong Liu - [email protected]; Lingqiu Gao - [email protected]; Irwin H Gelman* - [email protected] * Corresponding author Published: 25 April 2006 Received: 24 January 2006 Accepted: 25 April 2006 BMC Cancer2006, 6:105 doi:10.1186/1471-2407-6-105 This article is available from: http://www.biomedcentral.com/1471-2407/6/105 © 2006Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: SSeCKS is a major protein kinase C substrate with kinase scaffolding and metastasis- suppressor activity whose expression is severely downregulated in Src- and Ras-transformed fibroblast and epithelial cells and in human prostate, breast, and gastric cancers. We previously used NIH3T3 cells with tetracycline-regulated SSeCKS expression plus a temperature-sensitive v-Src allele to show that SSeCKS re-expression inhibited parameters of v-Src-induced oncogenic growth without attenuating in vivo Src kinase activity. Methods: We use cDNA microarrays and semi-quantitative RT-PCR analysis to identify changes in gene expression correlating with i) SSeCKS expression in the absence of v-Src activity, ii) activation of v-Src activity alone, and iii) SSeCKS re-expression in the presence of active v-Src.
    [Show full text]
  • Supplementary Table 2
    Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942
    [Show full text]